Protecting brain white matter from damage caused by reduced blood flow
Preconditioning brain white matter against ischemia
This study is looking at a drug called CX-4945 to see if it can help protect the brain's white matter from damage during strokes, especially in older adults, with the goal of finding better treatments to help stroke patients recover.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project ID | NIH-11057630 on NIH RePORTER |
What this research studies
This research investigates how to protect brain white matter from ischemic damage, particularly in aging populations who are at higher risk for strokes. The study focuses on a drug called CX-4945, which has shown promise in preconditioning brain tissue to withstand ischemic events. By understanding the mechanisms behind this protection, the research aims to develop effective treatments that can be applied in clinical settings to improve recovery outcomes for stroke patients. The approach includes both laboratory experiments and potential clinical applications to ensure relevance to patient care.
Who could benefit from this research
Good fit: Ideal candidates for this research are older adults who have experienced ischemic events or are at risk for strokes.
Not a fit: Patients who are not at risk for ischemic events or who have conditions unrelated to brain ischemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly improve recovery and quality of life for stroke survivors.
How similar studies have performed: Previous studies have shown success in using ischemic preconditioning in gray matter, but this approach in white matter is relatively novel and untested.
Where this research is happening
Portland, United States
- Oregon Health & Science University — Portland, United States (Active)
Researchers
- Principal investigator: Baltan, Selva — Oregon Health & Science University
- Study coordinator: Baltan, Selva
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.